Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Bleeding Stories

2013-07-05 23:00:09

Allegheny General Hospital In Pittsburgh, PA, has been awarded a two-year grant of $423,852 from the National Institute of Health (NIH) to fund a first-of-its-kind study that will attempt to determine how brain blood vessel tissue becomes vulnerable to aneurysm development and if there is a link between blood flow and vessel wall structure and strength. Pittsburgh, PA (PRWEB) July 06, 2013 Khaled Aziz, MD, Director of the Center for Complex Intracranial Surgery at Allegheny General...

2013-07-03 12:23:57

Data Presentations at ISTH Highlight Impact of Hemophilia on Health Care Utilization PLAINSBORO, N.J., July 3, 2013 /PRNewswire/ -- Novo Nordisk today announced findings from the Hemophilia Experiences, Results, and Opportunities (HERO) study showing that bleed frequency and treatment regimen choice impacted the use of health care resources and comprehensive care services among adults living with hemophilia. These results were presented in an oral presentation at the XXIV Congress of...

2013-07-02 04:21:24

Study Presented Today at the International Society on Thrombosis and Haemostasis Annual Meeting RARITAN, N.J., July 2, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates (PCCs) can reverse the blood thinning effects of XARELTO(®) (rivaroxaban) in healthy subjects. "PCCs can be used to reverse the blood...

2013-06-27 16:25:32

ANNAPOLIS, Md., June 27, 2013 /PRNewswire/ -- The Plasma Protein Therapeutics Association (PPTA) opposes New Jersey Senate Bill 2132 that imposes a new tax on therapies used to treat bleeding disorders such as hemophilia. Despite the opposition of the bill by the Pharmaceutical Research and Manufacturers of America (PhRMA); BioNJ; the Health Care Institute of New Jersey (HINJ); New Jersey Retail Merchants Association (NJRMA); New Jersey Business and Industry Association (NJBIA) and...

2013-06-25 23:26:56

Chaffin Luhana LLP warns heart patients that though the FDA has stated Pradaxa carries no more risk of bleeding than warfarin, a recent study questions that conclusion. New York, New York (PRWEB) June 25, 2013 Chaffin Luhana LLP, a national plaintiffs-only law firm, warns heart patients that though the FDA has stated Pradaxa carries no more risk of bleeding than warfarin, a recent study may show evidence that seems to be contrary to the FDA's conclusion. “Studies have been mixed on...

2013-06-25 08:29:10

MONTREAL, June 25, 2013 /PRNewswire/ - For 50 years, the World Federation of Hemophilia (WFH) has provided global leadership to improve and sustain care for people with inherited bleeding disorders, including hemophilia, von Willebrand disease, rare factor deficiencies, and inherited platelet disorders. Fifty years ago, on June 25, 1963, the WFH held its first meeting in Copenhagen, Denmark. Working with leaders from a group of national patient associations, Frank Schnabel, WFH...

2013-06-11 23:03:13

The Firm is currently investigating Pradaxa lawsuits on behalf of alleged victims of life-threatening Pradaxa bleeding. New York, New York (PRWEB) June 11, 2013 Pradaxa lawsuit claims continue to mount in the federal multidistrict litigation now underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to court filings 1,037 Pradaxa bleeding lawsuits have been filed in the proceeding, while the number of plaintiffs with claims in the...

2013-06-06 23:42:59

The US Drug Watchdog is urging victims of a transvaginal mesh failure involving severe bleeding to call them for the names, and contacts for the nation's leading transvaginal mesh lawyers, because continuous bleeding may be a symptom of erosion, and erosion may require one, or numerous corrective surgeries. For more information women, who are victims of a transvaginal mesh failure involving severe bleeding, or other serious medical complications are urged to contact the US Drug Watchdog...

2013-06-04 08:30:59

Results of Part 1 of the study will be presented at the 2013 International Society on Thrombosis and Haemostasis in Amsterdam, Netherlands on 2 July, 2013 KING OF PRUSSIA, Pa., June 4, 2013 /PRNewswire/ -- CSL Behring has dosed the first patient in Part 3 of its AFFINITY clinical trial program, which is now in phase III. AFFINITY is an open-label, non-randomized, multi-center study evaluating the efficacy, safety and pharmacokinetics of its novel investigational recombinant...

2013-05-28 12:25:01

A new guideline from the American Academy of Neurology will help people who take blood thinners decide whether or not to take them during surgery or other medical procedures. The guideline is published in the May 28, 2013, print issue of Neurology®, the medical journal of the American Academy of Neurology. People who have had a stroke often take blood thinners such as aspirin or warfarin to prevent another stroke. Blood thinners, or anticlotting drugs, are also used to prevent a first...